Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

By David R. Holmes III, Vivek Y. Reddy, Z. Turi, S. Doshi, H. Sievert, M. Buchbinder, C. Mullin, P. Sick. The Lancet, 2009

2,045 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3a1e84b71753bf6bb8154cff9c694e099dc9a61a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Siu
2. J. Halperin
3. C. Bushnell
4. C. Iadecola
5. M. Creager

In Pulmonary and Respiratory Medicine

1. S. Siu
2. C. Iadecola

Citations in the corpus

• Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). (2013, methodology): “Under TEE and fluoroscopic guidance, Watchman implantation was performed as previously described (10).”
• Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists (2007, background): “In addition, small pits and troughs can be seen around the orifice; each of these is thin walled, which may have implications for percutaneous devices.(127) Abnormal increases in thickness may be a result of laminar, mural thrombus or endocarditis.”
• 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. (2017, background): “The first RCT, PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation), randomized AF patients with a CHADS2 score (congestive heart failure, hypertension, 75 years of age or older, diabetes mellitus, and previous stroke or transient ischemic at”
• Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. (2014, background): “Siegel, Ashok Garg (Advanced Cardiac Specialists, Gilbert, Arizona [20]); Gregory Mishkel (PERC/St John’s Hospital, Springfield, Illinois [17]); Stephen Ramee (Ochsner Clinic, New Orleans, Louisiana [14]); Saibal Kar (Cedars-Sinai Medical Center, Los Angeles, California [16]); Brijeshwar Maini (Moff”